Claims for Patent: 10,227,295

Summary for Patent: 10,227,295

Title:	Selective histone deactylase 6 inhibitors
Abstract:	Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
Inventor(s):	Sotomayor; Eduardo M. (Tampa, FL), Bergman; Joel A. (Chicago, IL), Kozikowski; Alan P. (Chicago, IL), Villagra; Alejandro V. (Tampa, FL), Woan; Karrune V. (Gainesville, FL)
Assignee:	H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) Board of Trustees of The University of Illinois (Urbana, IL)
Application Number:	15/695,435
Patent Claims:	1. A method of treating melanoma in a subject, comprising: administering to the subject a therapeutically effective amount of a histone deacetylase inhibitor having a structure represented by Formula I: ##STR00037## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof. 2. The method of claim 1, wherein the inhibitor is a histone deacetylase 6 inhibitor. 3. The method of claim 1, wherein the inhibitor is Tubstatin A. 4. The method of claim 1, wherein the inhibitor is administered with one or more of ipilimumab, revlimid, velcade, vemurafenib, ST-3-06, ST-2-92, Tubstatin A, Tubacin. 5. The method of claim 1, wherein the inhibitor is combined with a STAT3 inhibitor. 6. A method of treating melanoma in a subject comprising administering a therapeutically effective amount of a cancer immunotherapy agent and a histone deacetylase inhibitor having a structure represented by Formula I: ##STR00038## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof. 7. The method of claim 6, wherein the immunotherapy agent is an antibody selected from anti-CLTA-4, anti-PD-1, or anti-PDL1. 8. The method of claim 6, wherein the immunotherapy agent is an IL-10 inhibitor. 9. A method of treating melanoma in a subject, comprising administering an effective amount of a toll like receptor agonist and a histone deactylase inhibitor having a structure represented by Formula I: ##STR00039## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof. 10. The method of claim 1, wherein A is phenyl, pyridyl, oxazolidyl, pyrimidyl, pyrimidinyl, or 1H-indazolyl, optionally substituted with C.sub.1-C.sub.5 alkyl, amino, alkoxy, alkylhydroxy, halo, hydroxy, or thiol. 11. The method of claim 1, wherein A is pyrimidinyl or 1H-indazolyl substituted with C.sub.1-C.sub.5 alkyl, C.sub.1-C.sub.4 alkoxyl, or halo. 12. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, or heteroaryl, any of which is optionally substituted with C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, carbonyl, hydroxy, thiol, or cyano. 13. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.5 alkyl, or C.sub.1-C.sub.5 alkyl substituted with a methoxy, amino, --NR.sup.6R.sup.7, alkylhydroxy, carbonyl, hydroxy, cyano. 14. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.4 alkyl. 15. The method of claim 1, wherein the structure according to Formula I is chosen from: ##STR00040##

Details for Patent 10,227,295

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2033-07-30